Guess you didn't read the paper -- it includes the details of the UCLA ATL vax formulation and vendors -- clearly not DCVax-L or using any of NWBO vendors. Read again.
DR, Robert Prins, one of the primary UCLA clinicians, has stated that UCAL has their own IND and that their two GBM combo trials and the NSCLC trial are using the UCLA DC vaccine, not DCVax-L.
Why would they use an out of data, 2 decade old formulation when they have had those two decades to improve the formulation using UCLA research.
News 
Market Data 
Discover 
AI
